nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—bone cancer	0.283	0.646	CtDrD
Sorafenib—kidney cancer—bone cancer	0.155	0.354	CtDrD
Sorafenib—BRAF—bone cancer	0.14	0.494	CbGaD
Sorafenib—KIT—bone cancer	0.113	0.396	CbGaD
Sorafenib—RALBP1—Doxorubicin—bone cancer	0.0628	0.384	CbGbCtD
Sorafenib—CYP3A4—bone cancer	0.0311	0.11	CbGaD
Sorafenib—ABCC2—Carboplatin—bone cancer	0.0115	0.0704	CbGbCtD
Sorafenib—ABCC4—Methotrexate—bone cancer	0.0107	0.0657	CbGbCtD
Sorafenib—ABCG2—Carboplatin—bone cancer	0.0104	0.0637	CbGbCtD
Sorafenib—ABCC2—Cisplatin—bone cancer	0.00983	0.0602	CbGbCtD
Sorafenib—ABCG2—Cisplatin—bone cancer	0.00889	0.0544	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—bone cancer	0.00659	0.0403	CbGbCtD
Sorafenib—ABCC2—Methotrexate—bone cancer	0.00638	0.0391	CbGbCtD
Sorafenib—CYP2B6—Cisplatin—bone cancer	0.00625	0.0383	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—bone cancer	0.00596	0.0365	CbGbCtD
Sorafenib—ABCG2—Methotrexate—bone cancer	0.00577	0.0353	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—bone cancer	0.00419	0.0256	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—bone cancer	0.0033	0.0202	CbGbCtD
Sorafenib—ABCB1—Cisplatin—bone cancer	0.0032	0.0196	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—bone cancer	0.00215	0.0131	CbGbCtD
Sorafenib—ABCB1—Methotrexate—bone cancer	0.00208	0.0127	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—bone cancer	0.00202	0.0124	CbGbCtD
Sorafenib—Vismodegib—SMO—bone cancer	0.00131	0.407	CrCbGaD
Sorafenib—CYP3A4—Doxorubicin—bone cancer	0.00129	0.00788	CbGbCtD
Sorafenib—CSF1R—periosteum—bone cancer	0.000904	0.0703	CbGeAlD
Sorafenib—Regorafenib—BRAF—bone cancer	0.000865	0.27	CrCbGaD
Sorafenib—Regorafenib—KIT—bone cancer	0.000694	0.216	CrCbGaD
Sorafenib—KDR—hindlimb—bone cancer	0.000659	0.0513	CbGeAlD
Sorafenib—MUSK—tendon—bone cancer	0.000603	0.047	CbGeAlD
Sorafenib—KDR—appendage—bone cancer	0.000565	0.044	CbGeAlD
Sorafenib—CDK7—connective tissue—bone cancer	0.000376	0.0293	CbGeAlD
Sorafenib—HIPK3—connective tissue—bone cancer	0.000318	0.0247	CbGeAlD
Sorafenib—FLT3—connective tissue—bone cancer	0.00027	0.021	CbGeAlD
Sorafenib—CDK7—Doxorubicin—Epirubicin—bone cancer	0.000267	0.173	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—bone cancer	0.000267	0.173	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Epirubicin—bone cancer	0.000267	0.173	CbGdCrCtD
Sorafenib—TAOK2—tendon—bone cancer	0.000256	0.0199	CbGeAlD
Sorafenib—AURKC—tendon—bone cancer	0.000254	0.0198	CbGeAlD
Sorafenib—CDK7—Idarubicin—Doxorubicin—bone cancer	0.000247	0.16	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—bone cancer	0.000247	0.16	CbGdCrCtD
Sorafenib—CDK7—Epirubicin—Doxorubicin—bone cancer	0.000247	0.16	CbGdCrCtD
Sorafenib—ZAK—tendon—bone cancer	0.000223	0.0174	CbGeAlD
Sorafenib—MKNK2—connective tissue—bone cancer	0.000222	0.0173	CbGeAlD
Sorafenib—HIPK3—tendon—bone cancer	0.000219	0.017	CbGeAlD
Sorafenib—RET—connective tissue—bone cancer	0.000217	0.0169	CbGeAlD
Sorafenib—HIPK3—bone marrow—bone cancer	0.000212	0.0165	CbGeAlD
Sorafenib—BRAF—tendon—bone cancer	0.000196	0.0152	CbGeAlD
Sorafenib—Regorafenib—CYP3A4—bone cancer	0.000192	0.0599	CrCbGaD
Sorafenib—FLT1—connective tissue—bone cancer	0.000191	0.0149	CbGeAlD
Sorafenib—RAF1—connective tissue—bone cancer	0.00019	0.0148	CbGeAlD
Sorafenib—BRAF—bone marrow—bone cancer	0.00019	0.0148	CbGeAlD
Sorafenib—EPHX2—tendon—bone cancer	0.000187	0.0146	CbGeAlD
Sorafenib—FLT3—bone marrow—bone cancer	0.00018	0.014	CbGeAlD
Sorafenib—PDGFRA—connective tissue—bone cancer	0.000179	0.0139	CbGeAlD
Sorafenib—FGFR1—tendon—bone cancer	0.000167	0.013	CbGeAlD
Sorafenib—FLT4—bone marrow—bone cancer	0.000163	0.0127	CbGeAlD
Sorafenib—KDR—connective tissue—bone cancer	0.000161	0.0126	CbGeAlD
Sorafenib—FGFR1—spinal cord—bone cancer	0.000161	0.0125	CbGeAlD
Sorafenib—MAP3K7—tendon—bone cancer	0.000158	0.0123	CbGeAlD
Sorafenib—CSF1R—connective tissue—bone cancer	0.000158	0.0123	CbGeAlD
Sorafenib—MKNK2—tendon—bone cancer	0.000153	0.0119	CbGeAlD
Sorafenib—MAP3K7—bone marrow—bone cancer	0.000153	0.0119	CbGeAlD
Sorafenib—Vismodegib—CYP3A4—bone cancer	0.000152	0.0475	CrCbGaD
Sorafenib—MAP3K7—spinal cord—bone cancer	0.000152	0.0118	CbGeAlD
Sorafenib—RET—tendon—bone cancer	0.000149	0.0116	CbGeAlD
Sorafenib—MKNK2—bone marrow—bone cancer	0.000148	0.0115	CbGeAlD
Sorafenib—MKNK2—spinal cord—bone cancer	0.000147	0.0115	CbGeAlD
Sorafenib—MKNK1—bone marrow—bone cancer	0.000146	0.0114	CbGeAlD
Sorafenib—MKNK1—spinal cord—bone cancer	0.000145	0.0113	CbGeAlD
Sorafenib—RET—spinal cord—bone cancer	0.000144	0.0112	CbGeAlD
Sorafenib—KIT—connective tissue—bone cancer	0.000143	0.0111	CbGeAlD
Sorafenib—PDGFRB—connective tissue—bone cancer	0.00014	0.0109	CbGeAlD
Sorafenib—RALBP1—tendon—bone cancer	0.000138	0.0107	CbGeAlD
Sorafenib—RALBP1—bone marrow—bone cancer	0.000134	0.0104	CbGeAlD
Sorafenib—RALBP1—spinal cord—bone cancer	0.000133	0.0104	CbGeAlD
Sorafenib—FLT1—tendon—bone cancer	0.000131	0.0102	CbGeAlD
Sorafenib—RAF1—tendon—bone cancer	0.00013	0.0102	CbGeAlD
Sorafenib—EPHB6—tendon—bone cancer	0.00013	0.0101	CbGeAlD
Sorafenib—FLT1—spinal cord—bone cancer	0.000127	0.00985	CbGeAlD
Sorafenib—RAF1—bone marrow—bone cancer	0.000126	0.00983	CbGeAlD
Sorafenib—RAF1—spinal cord—bone cancer	0.000126	0.00979	CbGeAlD
Sorafenib—EPHB6—spinal cord—bone cancer	0.000125	0.00974	CbGeAlD
Sorafenib—STK10—tendon—bone cancer	0.000124	0.00967	CbGeAlD
Sorafenib—PDGFRA—tendon—bone cancer	0.000123	0.00957	CbGeAlD
Sorafenib—STK10—bone marrow—bone cancer	0.00012	0.00936	CbGeAlD
Sorafenib—PDGFRA—spinal cord—bone cancer	0.000119	0.00923	CbGeAlD
Sorafenib—KDR—tendon—bone cancer	0.000111	0.00863	CbGeAlD
Sorafenib—MAP2K5—tendon—bone cancer	0.000111	0.00863	CbGeAlD
Sorafenib—CSF1R—tendon—bone cancer	0.000108	0.00843	CbGeAlD
Sorafenib—KDR—bone marrow—bone cancer	0.000107	0.00836	CbGeAlD
Sorafenib—KDR—spinal cord—bone cancer	0.000107	0.00833	CbGeAlD
Sorafenib—MAP2K5—spinal cord—bone cancer	0.000107	0.00833	CbGeAlD
Sorafenib—CSF1R—bone marrow—bone cancer	0.000105	0.00816	CbGeAlD
Sorafenib—CSF1R—spinal cord—bone cancer	0.000104	0.00813	CbGeAlD
Sorafenib—PDGFRB—tendon—bone cancer	9.6e-05	0.00747	CbGeAlD
Sorafenib—KIT—bone marrow—bone cancer	9.52e-05	0.00741	CbGeAlD
Sorafenib—KIT—spinal cord—bone cancer	9.48e-05	0.00738	CbGeAlD
Sorafenib—PDGFRB—bone marrow—bone cancer	9.3e-05	0.00724	CbGeAlD
Sorafenib—PDGFRB—spinal cord—bone cancer	9.26e-05	0.00721	CbGeAlD
Sorafenib—Breast disorder—Methotrexate—bone cancer	8.21e-05	0.00208	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—bone cancer	8.19e-05	0.00208	CcSEcCtD
Sorafenib—Anaphylactic shock—Cisplatin—bone cancer	8.14e-05	0.00207	CcSEcCtD
Sorafenib—Infection—Cisplatin—bone cancer	8.09e-05	0.00205	CcSEcCtD
Sorafenib—Cardiac failure—Doxorubicin—bone cancer	8.07e-05	0.00205	CcSEcCtD
Sorafenib—Mood swings—Epirubicin—bone cancer	8.06e-05	0.00204	CcSEcCtD
Sorafenib—Nervous system disorder—Cisplatin—bone cancer	7.98e-05	0.00203	CcSEcCtD
Sorafenib—Thrombocytopenia—Cisplatin—bone cancer	7.97e-05	0.00202	CcSEcCtD
Sorafenib—Dehydration—Epirubicin—bone cancer	7.91e-05	0.00201	CcSEcCtD
Sorafenib—Skin disorder—Cisplatin—bone cancer	7.91e-05	0.00201	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—bone cancer	7.9e-05	0.00201	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—bone cancer	7.87e-05	0.002	CcSEcCtD
Sorafenib—HTR2C—spinal cord—bone cancer	7.81e-05	0.00608	CbGeAlD
Sorafenib—Dry skin—Epirubicin—bone cancer	7.8e-05	0.00198	CcSEcCtD
Sorafenib—Abdominal pain upper—Epirubicin—bone cancer	7.77e-05	0.00197	CcSEcCtD
Sorafenib—Anorexia—Cisplatin—bone cancer	7.76e-05	0.00197	CcSEcCtD
Sorafenib—Hypokalaemia—Epirubicin—bone cancer	7.74e-05	0.00196	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—bone cancer	7.7e-05	0.00195	CcSEcCtD
Sorafenib—Breast disorder—Epirubicin—bone cancer	7.69e-05	0.00195	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—bone cancer	7.66e-05	0.00194	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—bone cancer	7.66e-05	0.00194	CcSEcCtD
Sorafenib—ABCC4—tendon—bone cancer	7.65e-05	0.00595	CbGeAlD
Sorafenib—Nasopharyngitis—Epirubicin—bone cancer	7.61e-05	0.00193	CcSEcCtD
Sorafenib—HTR2B—tendon—bone cancer	7.61e-05	0.00592	CbGeAlD
Sorafenib—Abdominal discomfort—Methotrexate—bone cancer	7.53e-05	0.00191	CcSEcCtD
Sorafenib—Gastritis—Epirubicin—bone cancer	7.53e-05	0.00191	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—bone cancer	7.5e-05	0.0019	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—bone cancer	7.46e-05	0.00189	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Cisplatin—bone cancer	7.42e-05	0.00188	CcSEcCtD
Sorafenib—ABCC4—bone marrow—bone cancer	7.41e-05	0.00576	CbGeAlD
Sorafenib—ABCC2—tendon—bone cancer	7.4e-05	0.00576	CbGeAlD
Sorafenib—Dysphagia—Epirubicin—bone cancer	7.35e-05	0.00187	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—bone cancer	7.35e-05	0.00186	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—bone cancer	7.32e-05	0.00186	CcSEcCtD
Sorafenib—Dyspnoea—Cisplatin—bone cancer	7.26e-05	0.00184	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—bone cancer	7.24e-05	0.00184	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—bone cancer	7.21e-05	0.00183	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—bone cancer	7.21e-05	0.00183	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—bone cancer	7.19e-05	0.00182	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—bone cancer	7.16e-05	0.00182	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—bone cancer	7.11e-05	0.0018	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	7.09e-05	0.0018	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—bone cancer	7.09e-05	0.0018	CcSEcCtD
Sorafenib—Decreased appetite—Cisplatin—bone cancer	7.08e-05	0.0018	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—bone cancer	7.05e-05	0.00179	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—bone cancer	7.04e-05	0.00179	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cisplatin—bone cancer	7.03e-05	0.00178	CcSEcCtD
Sorafenib—Infestation—Methotrexate—bone cancer	7.01e-05	0.00178	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—bone cancer	7.01e-05	0.00178	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—bone cancer	6.97e-05	0.00177	CcSEcCtD
Sorafenib—Pain—Cisplatin—bone cancer	6.96e-05	0.00177	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—bone cancer	6.95e-05	0.00176	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—bone cancer	6.94e-05	0.00176	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—bone cancer	6.89e-05	0.00175	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—bone cancer	6.88e-05	0.00174	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—bone cancer	6.83e-05	0.00173	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—bone cancer	6.8e-05	0.00173	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—bone cancer	6.67e-05	0.00169	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—bone cancer	6.65e-05	0.00169	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—bone cancer	6.63e-05	0.00168	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—bone cancer	6.61e-05	0.00168	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—bone cancer	6.59e-05	0.00167	CcSEcCtD
Sorafenib—Infestation—Epirubicin—bone cancer	6.56e-05	0.00166	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—bone cancer	6.56e-05	0.00166	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—bone cancer	6.5e-05	0.00165	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—bone cancer	6.44e-05	0.00164	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—bone cancer	6.44e-05	0.00163	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—bone cancer	6.43e-05	0.00163	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—bone cancer	6.39e-05	0.00162	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—bone cancer	6.39e-05	0.00162	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—bone cancer	6.36e-05	0.00161	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—bone cancer	6.32e-05	0.0016	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—bone cancer	6.29e-05	0.0016	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—bone cancer	6.21e-05	0.00158	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—bone cancer	6.2e-05	0.00157	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—bone cancer	6.18e-05	0.00157	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—bone cancer	6.16e-05	0.00156	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—bone cancer	6.15e-05	0.00156	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—bone cancer	6.1e-05	0.00155	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—bone cancer	6.07e-05	0.00154	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—bone cancer	6.07e-05	0.00154	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	6.01e-05	0.00153	CcSEcCtD
Sorafenib—Hypersensitivity—Cisplatin—bone cancer	6e-05	0.00152	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—bone cancer	5.96e-05	0.00151	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—bone cancer	5.95e-05	0.00151	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—bone cancer	5.95e-05	0.00151	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—bone cancer	5.92e-05	0.0015	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—bone cancer	5.91e-05	0.0015	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—bone cancer	5.91e-05	0.0015	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—bone cancer	5.89e-05	0.00149	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—bone cancer	5.86e-05	0.00149	CcSEcCtD
Sorafenib—Asthenia—Cisplatin—bone cancer	5.84e-05	0.00148	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—bone cancer	5.84e-05	0.00148	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—bone cancer	5.81e-05	0.00147	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—bone cancer	5.78e-05	0.00147	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—bone cancer	5.77e-05	0.00146	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—bone cancer	5.74e-05	0.00146	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—bone cancer	5.72e-05	0.00145	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—bone cancer	5.71e-05	0.00145	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—bone cancer	5.68e-05	0.00144	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—bone cancer	5.67e-05	0.00144	CcSEcCtD
Sorafenib—Diarrhoea—Cisplatin—bone cancer	5.57e-05	0.00141	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—bone cancer	5.56e-05	0.00141	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—bone cancer	5.56e-05	0.00141	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—bone cancer	5.51e-05	0.0014	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—bone cancer	5.49e-05	0.00139	CcSEcCtD
Sorafenib—Erythema—Methotrexate—bone cancer	5.47e-05	0.00139	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—bone cancer	5.47e-05	0.00139	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—bone cancer	5.47e-05	0.00139	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—bone cancer	5.46e-05	0.00139	CcSEcCtD
Sorafenib—Flushing—Epirubicin—bone cancer	5.46e-05	0.00139	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—bone cancer	5.45e-05	0.00138	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—bone cancer	5.38e-05	0.00136	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—bone cancer	5.36e-05	0.00136	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—bone cancer	5.35e-05	0.00136	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—bone cancer	5.34e-05	0.00135	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—bone cancer	5.34e-05	0.00135	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—bone cancer	5.32e-05	0.00135	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—bone cancer	5.3e-05	0.00135	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—bone cancer	5.26e-05	0.00133	CcSEcCtD
Sorafenib—ABCG2—bone marrow—bone cancer	5.23e-05	0.00407	CbGeAlD
Sorafenib—ABCG2—spinal cord—bone cancer	5.21e-05	0.00405	CbGeAlD
Sorafenib—Alopecia—Epirubicin—bone cancer	5.2e-05	0.00132	CcSEcCtD
Sorafenib—Vomiting—Cisplatin—bone cancer	5.18e-05	0.00131	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—bone cancer	5.16e-05	0.00131	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—bone cancer	5.15e-05	0.00131	CcSEcCtD
Sorafenib—Rash—Cisplatin—bone cancer	5.13e-05	0.0013	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—bone cancer	5.13e-05	0.0013	CcSEcCtD
Sorafenib—Erythema—Epirubicin—bone cancer	5.12e-05	0.0013	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—bone cancer	5.12e-05	0.0013	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—bone cancer	5.08e-05	0.00129	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—bone cancer	5.06e-05	0.00128	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—bone cancer	5.05e-05	0.00128	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—bone cancer	5.05e-05	0.00128	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—bone cancer	5.02e-05	0.00127	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—bone cancer	4.94e-05	0.00125	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—bone cancer	4.93e-05	0.00125	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—bone cancer	4.92e-05	0.00125	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—bone cancer	4.91e-05	0.00125	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—bone cancer	4.9e-05	0.00124	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—bone cancer	4.86e-05	0.00123	CcSEcCtD
Sorafenib—Nausea—Cisplatin—bone cancer	4.84e-05	0.00123	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—bone cancer	4.81e-05	0.00122	CcSEcCtD
Sorafenib—Cough—Methotrexate—bone cancer	4.78e-05	0.00121	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—bone cancer	4.77e-05	0.00121	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—bone cancer	4.74e-05	0.0012	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—bone cancer	4.74e-05	0.0012	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—bone cancer	4.74e-05	0.0012	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—bone cancer	4.66e-05	0.00118	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—bone cancer	4.66e-05	0.00118	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—bone cancer	4.64e-05	0.00118	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	4.63e-05	0.00117	CcSEcCtD
Sorafenib—Syncope—Epirubicin—bone cancer	4.59e-05	0.00117	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—bone cancer	4.59e-05	0.00116	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—bone cancer	4.56e-05	0.00116	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—bone cancer	4.5e-05	0.00114	CcSEcCtD
Sorafenib—Cough—Epirubicin—bone cancer	4.47e-05	0.00113	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—bone cancer	4.47e-05	0.00113	CcSEcCtD
Sorafenib—Infection—Methotrexate—bone cancer	4.44e-05	0.00113	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—bone cancer	4.42e-05	0.00112	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—bone cancer	4.38e-05	0.00111	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—bone cancer	4.38e-05	0.00111	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—bone cancer	4.37e-05	0.00111	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—bone cancer	4.36e-05	0.00111	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—bone cancer	4.36e-05	0.00111	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—bone cancer	4.34e-05	0.0011	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	4.33e-05	0.0011	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—bone cancer	4.27e-05	0.00108	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—bone cancer	4.26e-05	0.00108	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—bone cancer	4.25e-05	0.00108	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—bone cancer	4.24e-05	0.00108	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—bone cancer	4.18e-05	0.00106	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—bone cancer	4.17e-05	0.00106	CcSEcCtD
Sorafenib—Infection—Epirubicin—bone cancer	4.15e-05	0.00105	CcSEcCtD
Sorafenib—Cough—Doxorubicin—bone cancer	4.14e-05	0.00105	CcSEcCtD
Sorafenib—Shock—Epirubicin—bone cancer	4.11e-05	0.00104	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—bone cancer	4.1e-05	0.00104	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—bone cancer	4.09e-05	0.00104	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—bone cancer	4.09e-05	0.00104	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—bone cancer	4.07e-05	0.00103	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—bone cancer	4.06e-05	0.00103	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—bone cancer	4.04e-05	0.00102	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—bone cancer	4.04e-05	0.00102	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.01e-05	0.00102	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—bone cancer	3.99e-05	0.00101	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—bone cancer	3.98e-05	0.00101	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—bone cancer	3.95e-05	0.001	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—bone cancer	3.93e-05	0.000998	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—bone cancer	3.88e-05	0.000985	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—bone cancer	3.87e-05	0.000982	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—bone cancer	3.86e-05	0.000979	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—bone cancer	3.85e-05	0.000977	CcSEcCtD
Sorafenib—Infection—Doxorubicin—bone cancer	3.84e-05	0.000975	CcSEcCtD
Sorafenib—Pain—Methotrexate—bone cancer	3.82e-05	0.000969	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—bone cancer	3.81e-05	0.000967	CcSEcCtD
Sorafenib—Shock—Doxorubicin—bone cancer	3.81e-05	0.000966	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—bone cancer	3.79e-05	0.000963	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—bone cancer	3.79e-05	0.000961	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—bone cancer	3.76e-05	0.000953	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—bone cancer	3.73e-05	0.000946	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—bone cancer	3.69e-05	0.000936	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—bone cancer	3.68e-05	0.000934	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—bone cancer	3.65e-05	0.000927	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—bone cancer	3.63e-05	0.000922	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—bone cancer	3.61e-05	0.000916	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—bone cancer	3.6e-05	0.000915	CcSEcCtD
Sorafenib—Constipation—Epirubicin—bone cancer	3.58e-05	0.000907	CcSEcCtD
Sorafenib—Pain—Epirubicin—bone cancer	3.58e-05	0.000907	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—bone cancer	3.55e-05	0.000901	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—bone cancer	3.53e-05	0.000896	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—bone cancer	3.53e-05	0.000896	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.52e-05	0.000894	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—bone cancer	3.45e-05	0.000875	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—bone cancer	3.42e-05	0.000868	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—bone cancer	3.41e-05	0.000864	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—bone cancer	3.36e-05	0.000853	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—bone cancer	3.34e-05	0.000847	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—bone cancer	3.34e-05	0.000846	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—bone cancer	3.32e-05	0.000843	CcSEcCtD
Sorafenib—Pain—Doxorubicin—bone cancer	3.31e-05	0.000839	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—bone cancer	3.31e-05	0.000839	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—bone cancer	3.31e-05	0.000839	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—bone cancer	3.31e-05	0.000839	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—bone cancer	3.29e-05	0.000835	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—bone cancer	3.21e-05	0.000813	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—bone cancer	3.16e-05	0.000803	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—bone cancer	3.16e-05	0.000802	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—bone cancer	3.08e-05	0.000782	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—bone cancer	3.07e-05	0.00078	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—bone cancer	3.06e-05	0.000776	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—bone cancer	3.06e-05	0.000776	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—bone cancer	3.06e-05	0.000776	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—bone cancer	3e-05	0.000761	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—bone cancer	2.96e-05	0.000751	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—bone cancer	2.95e-05	0.00075	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—bone cancer	2.86e-05	0.000726	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—bone cancer	2.85e-05	0.000723	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—bone cancer	2.84e-05	0.000721	CcSEcCtD
Sorafenib—Rash—Methotrexate—bone cancer	2.82e-05	0.000715	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—bone cancer	2.81e-05	0.000714	CcSEcCtD
Sorafenib—Headache—Methotrexate—bone cancer	2.8e-05	0.00071	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—bone cancer	2.78e-05	0.000704	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—bone cancer	2.76e-05	0.000702	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—bone cancer	2.74e-05	0.000695	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—bone cancer	2.66e-05	0.000675	CcSEcCtD
Sorafenib—Nausea—Methotrexate—bone cancer	2.65e-05	0.000673	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—bone cancer	2.65e-05	0.000672	CcSEcCtD
Sorafenib—Rash—Epirubicin—bone cancer	2.64e-05	0.000669	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—bone cancer	2.63e-05	0.000668	CcSEcCtD
Sorafenib—Headache—Epirubicin—bone cancer	2.62e-05	0.000665	CcSEcCtD
Sorafenib—ABCB1—bone marrow—bone cancer	2.58e-05	0.00201	CbGeAlD
Sorafenib—ABCB1—spinal cord—bone cancer	2.57e-05	0.002	CbGeAlD
Sorafenib—Dizziness—Doxorubicin—bone cancer	2.56e-05	0.000649	CcSEcCtD
Sorafenib—Nausea—Epirubicin—bone cancer	2.48e-05	0.00063	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—bone cancer	2.46e-05	0.000624	CcSEcCtD
Sorafenib—Rash—Doxorubicin—bone cancer	2.44e-05	0.000619	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—bone cancer	2.44e-05	0.000618	CcSEcCtD
Sorafenib—Headache—Doxorubicin—bone cancer	2.42e-05	0.000615	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—bone cancer	2.3e-05	0.000583	CcSEcCtD
Sorafenib—FLT4—Signaling Pathways—EGFR—bone cancer	3.74e-06	6.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL3—bone cancer	3.73e-06	6.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFBR2—bone cancer	3.72e-06	6.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFBR2—bone cancer	3.71e-06	6.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—JUN—bone cancer	3.69e-06	6.47e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IGF1R—bone cancer	3.69e-06	6.45e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IGF1R—bone cancer	3.69e-06	6.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—EGFR—bone cancer	3.67e-06	6.42e-05	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—EGFR—bone cancer	3.67e-06	6.42e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—GSTP1—bone cancer	3.66e-06	6.41e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—GSTP1—bone cancer	3.66e-06	6.41e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CYP3A4—bone cancer	3.63e-06	6.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—EGFR—bone cancer	3.63e-06	6.35e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SMO—bone cancer	3.62e-06	6.35e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KIT—bone cancer	3.62e-06	6.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—EGFR—bone cancer	3.62e-06	6.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KIT—bone cancer	3.61e-06	6.33e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—MDM2—bone cancer	3.61e-06	6.32e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CYP3A4—bone cancer	3.6e-06	6.3e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—BRAF—bone cancer	3.59e-06	6.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ATF1—bone cancer	3.57e-06	6.25e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—JUN—bone cancer	3.55e-06	6.21e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KIT—bone cancer	3.54e-06	6.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KIT—bone cancer	3.53e-06	6.17e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NT5C3A—bone cancer	3.51e-06	6.15e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IGF1R—bone cancer	3.5e-06	6.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IGF1R—bone cancer	3.49e-06	6.11e-05	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—EGFR—bone cancer	3.48e-06	6.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL3—bone cancer	3.48e-06	6.1e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—EGFR—bone cancer	3.47e-06	6.08e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP9—bone cancer	3.45e-06	6.04e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KIT—bone cancer	3.45e-06	6.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—BRAF—bone cancer	3.41e-06	5.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—BRAF—bone cancer	3.4e-06	5.95e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ENO2—bone cancer	3.39e-06	5.93e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFBR2—bone cancer	3.34e-06	5.85e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—BRAF—bone cancer	3.33e-06	5.82e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.32e-06	5.81e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—GNA11—bone cancer	3.32e-06	5.81e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ENO2—bone cancer	3.31e-06	5.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MDM2—bone cancer	3.3e-06	5.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—EGFR—bone cancer	3.29e-06	5.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—EGFR—bone cancer	3.26e-06	5.71e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MDM2—bone cancer	3.26e-06	5.7e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—MDM2—bone cancer	3.26e-06	5.7e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KIT—bone cancer	3.26e-06	5.7e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—BRAF—bone cancer	3.24e-06	5.67e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—bone cancer	3.22e-06	5.64e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—bone cancer	3.19e-06	5.59e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFBR2—bone cancer	3.19e-06	5.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—PTGS2—bone cancer	3.18e-06	5.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	3.14e-06	5.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KIT—bone cancer	3.14e-06	5.5e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—DHFR—bone cancer	3.14e-06	5.5e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—JUN—bone cancer	3.14e-06	5.5e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—bone cancer	3.14e-06	5.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	3.13e-06	5.48e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—EGFR—bone cancer	3.12e-06	5.46e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GSTP1—bone cancer	3.11e-06	5.44e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—EGFR—bone cancer	3.1e-06	5.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—MDM2—bone cancer	3.09e-06	5.41e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MDM2—bone cancer	3.08e-06	5.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ATF1—bone cancer	3.08e-06	5.4e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GSTP1—bone cancer	3.08e-06	5.39e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—DHFR—bone cancer	3.07e-06	5.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—BRAF—bone cancer	3.06e-06	5.36e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MDM2—bone cancer	3.01e-06	5.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL3—bone cancer	3.01e-06	5.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IGF1R—bone cancer	3e-06	5.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFBR2—bone cancer	2.98e-06	5.21e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KIT—bone cancer	2.96e-06	5.19e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KIT—bone cancer	2.94e-06	5.14e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GNA11—bone cancer	2.94e-06	5.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—EGFR—bone cancer	2.9e-06	5.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KIT—bone cancer	2.9e-06	5.08e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTGS2—bone cancer	2.9e-06	5.08e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GNA11—bone cancer	2.87e-06	5.03e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ENO2—bone cancer	2.87e-06	5.02e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MDM2—bone cancer	2.85e-06	5e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MDM2—bone cancer	2.85e-06	4.98e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—JUN—bone cancer	2.83e-06	4.96e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—JUN—bone cancer	2.83e-06	4.96e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1R—bone cancer	2.8e-06	4.91e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EGFR—bone cancer	2.79e-06	4.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—EGFR—bone cancer	2.79e-06	4.88e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—BRAF—bone cancer	2.79e-06	4.88e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MDM2—bone cancer	2.79e-06	4.88e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.78e-06	4.88e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—MDM2—bone cancer	2.78e-06	4.86e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTGS2—bone cancer	2.75e-06	4.82e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTGS2—bone cancer	2.74e-06	4.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—BRAF—bone cancer	2.73e-06	4.78e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MDM2—bone cancer	2.72e-06	4.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—bone cancer	2.71e-06	4.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—JUN—bone cancer	2.69e-06	4.7e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—JUN—bone cancer	2.68e-06	4.69e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KIT—bone cancer	2.67e-06	4.68e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP3A4—bone cancer	2.66e-06	4.66e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—DHFR—bone cancer	2.66e-06	4.66e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP3A4—bone cancer	2.6e-06	4.56e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—bone cancer	2.6e-06	4.55e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFBR2—bone cancer	2.57e-06	4.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MDM2—bone cancer	2.56e-06	4.49e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ENO2—bone cancer	2.56e-06	4.48e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KIT—bone cancer	2.54e-06	4.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KIT—bone cancer	2.53e-06	4.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—BRAF—bone cancer	2.51e-06	4.4e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—BRAF—bone cancer	2.51e-06	4.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ENO2—bone cancer	2.5e-06	4.37e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNA11—bone cancer	2.49e-06	4.35e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MDM2—bone cancer	2.48e-06	4.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—bone cancer	2.47e-06	4.33e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EGFR—bone cancer	2.47e-06	4.32e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—JUN—bone cancer	2.42e-06	4.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1R—bone cancer	2.42e-06	4.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—JUN—bone cancer	2.41e-06	4.23e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—BRAF—bone cancer	2.38e-06	4.18e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—BRAF—bone cancer	2.38e-06	4.17e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—DHFR—bone cancer	2.37e-06	4.16e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—JUN—bone cancer	2.36e-06	4.13e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—bone cancer	2.36e-06	4.13e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO2—bone cancer	2.35e-06	4.12e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—bone cancer	2.34e-06	4.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MDM2—bone cancer	2.33e-06	4.09e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO2—bone cancer	2.33e-06	4.09e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—DHFR—bone cancer	2.32e-06	4.06e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MDM2—bone cancer	2.31e-06	4.05e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—bone cancer	2.3e-06	4.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MDM2—bone cancer	2.29e-06	4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KIT—bone cancer	2.28e-06	3.99e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GSTP1—bone cancer	2.28e-06	3.99e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—bone cancer	2.26e-06	3.95e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP3A4—bone cancer	2.25e-06	3.95e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.24e-06	3.93e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GSTP1—bone cancer	2.23e-06	3.9e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—bone cancer	2.23e-06	3.9e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—bone cancer	2.23e-06	3.9e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNA11—bone cancer	2.22e-06	3.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—bone cancer	2.2e-06	3.86e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—DHFR—bone cancer	2.18e-06	3.82e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KIT—bone cancer	2.17e-06	3.81e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNA11—bone cancer	2.17e-06	3.79e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—DHFR—bone cancer	2.16e-06	3.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—JUN—bone cancer	2.15e-06	3.77e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—BRAF—bone cancer	2.14e-06	3.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—bone cancer	2.11e-06	3.7e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—bone cancer	2.11e-06	3.69e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MDM2—bone cancer	2.11e-06	3.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MDM2—bone cancer	2.11e-06	3.69e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—bone cancer	2.05e-06	3.6e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—BRAF—bone cancer	2.04e-06	3.58e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNA11—bone cancer	2.04e-06	3.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KIT—bone cancer	2.03e-06	3.56e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—JUN—bone cancer	2.03e-06	3.55e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNA11—bone cancer	2.02e-06	3.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP3A4—bone cancer	2.01e-06	3.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—JUN—bone cancer	2.01e-06	3.52e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2e-06	3.51e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MDM2—bone cancer	2e-06	3.5e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO2—bone cancer	1.99e-06	3.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MDM2—bone cancer	1.99e-06	3.49e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—bone cancer	1.98e-06	3.47e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—bone cancer	1.97e-06	3.46e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP3A4—bone cancer	1.96e-06	3.44e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—bone cancer	1.96e-06	3.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—bone cancer	1.95e-06	3.41e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—bone cancer	1.94e-06	3.41e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTP1—bone cancer	1.93e-06	3.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—BRAF—bone cancer	1.91e-06	3.34e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—bone cancer	1.9e-06	3.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—bone cancer	1.9e-06	3.32e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—bone cancer	1.9e-06	3.32e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—bone cancer	1.9e-06	3.32e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—bone cancer	1.86e-06	3.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—bone cancer	1.85e-06	3.24e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP3A4—bone cancer	1.85e-06	3.24e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—DHFR—bone cancer	1.85e-06	3.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP3A4—bone cancer	1.83e-06	3.21e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—JUN—bone cancer	1.83e-06	3.2e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—JUN—bone cancer	1.83e-06	3.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.83e-06	3.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MDM2—bone cancer	1.8e-06	3.14e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—bone cancer	1.78e-06	3.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—bone cancer	1.78e-06	3.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—bone cancer	1.75e-06	3.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—bone cancer	1.75e-06	3.07e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—JUN—bone cancer	1.74e-06	3.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—JUN—bone cancer	1.73e-06	3.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNA11—bone cancer	1.73e-06	3.03e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTP1—bone cancer	1.72e-06	3.01e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MDM2—bone cancer	1.71e-06	3e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—bone cancer	1.69e-06	2.96e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—bone cancer	1.69e-06	2.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—bone cancer	1.69e-06	2.95e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTP1—bone cancer	1.68e-06	2.94e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—BRAF—bone cancer	1.65e-06	2.89e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—bone cancer	1.61e-06	2.82e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MDM2—bone cancer	1.6e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—bone cancer	1.6e-06	2.8e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.6e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—bone cancer	1.6e-06	2.79e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—bone cancer	1.6e-06	2.79e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTP1—bone cancer	1.58e-06	2.77e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—bone cancer	1.58e-06	2.77e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTP1—bone cancer	1.57e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP3A4—bone cancer	1.57e-06	2.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—bone cancer	1.56e-06	2.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JUN—bone cancer	1.56e-06	2.73e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.56e-06	2.73e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—bone cancer	1.56e-06	2.73e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—bone cancer	1.54e-06	2.7e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—bone cancer	1.52e-06	2.66e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—bone cancer	1.49e-06	2.61e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—bone cancer	1.45e-06	2.54e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—bone cancer	1.44e-06	2.52e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—bone cancer	1.44e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—DHFR—bone cancer	1.43e-06	2.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—bone cancer	1.39e-06	2.44e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MDM2—bone cancer	1.38e-06	2.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—bone cancer	1.37e-06	2.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—bone cancer	1.36e-06	2.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—bone cancer	1.35e-06	2.37e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—bone cancer	1.34e-06	2.35e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—bone cancer	1.34e-06	2.35e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNA11—bone cancer	1.33e-06	2.34e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—bone cancer	1.33e-06	2.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—bone cancer	1.23e-06	2.15e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—bone cancer	1.21e-06	2.12e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—bone cancer	1.21e-06	2.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—bone cancer	1.2e-06	2.1e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—bone cancer	1.18e-06	2.07e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—bone cancer	1.17e-06	2.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—bone cancer	1.17e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—bone cancer	1.15e-06	2.02e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—bone cancer	1.15e-06	2.01e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—bone cancer	1.14e-06	2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—bone cancer	1.09e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—bone cancer	1.03e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—bone cancer	1.03e-06	1.8e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—bone cancer	9.99e-07	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—bone cancer	9.82e-07	1.72e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—bone cancer	9.44e-07	1.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—bone cancer	9.18e-07	1.61e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—bone cancer	8.91e-07	1.56e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—bone cancer	8.7e-07	1.52e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—bone cancer	8.2e-07	1.44e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—bone cancer	8.13e-07	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—bone cancer	7.93e-07	1.39e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—bone cancer	6.95e-07	1.22e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—bone cancer	5.36e-07	9.39e-06	CbGpPWpGaD
